Animal Pharm's Top 20: 2006 Edition

SUMMARY

Animal Pharm's Top 20 is recognised throughout the animal health and nutrition industry as a key source of information and analysis on the 20 largest companies in the sector. Invest in this report to keep informed of the performance of your potential competitors, collaborators or customers.

Key Findings:

• Global sales of animal health and nutrition products totalled almost US$21.7 billion in 2005. That figure was around 7% higher than the year-earlier total of US$20.3 billion.
• Sales of veterinary pharmaceuticals and biologicals for use in small animals alone are now worth almost US$6 billion, a figure equivalent to more than 27% of the entire market.
• The 13% increase in revenues reported by Pfizer Animal Health in 2005 saw the company consolidate its position at the head of the global sales league, with a gap of more than US$200 million between it and second-placed Merial.
• Merial appears set to leapfrog Pfizer in 2006, regaining the leadership position it held prior to Pfizer's acquisition of Pharmacia Corp in 2003.
• The acquisition of Adisseo by the China National Chemical Corp (CNCC), announced late in 2005 and completed in 2006, is among the most significant M&A developments reported recently in the industry.
• Despite SPAH's recent problems in the US market, most recent results indicate that the worst may finally be behind the company, with US sales up sharply on year-earlier figures in the first half of 2006.
• Merial's Frontline sales fell back by 11% on year-earlier figures in the third quarter of 2005. That was followed by a 31% gain in the final quarter, however, and further strong growth through the first half of 2006.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION

• 1.1 The world market for animal health and nutrition products
  • 1.1.1 Market shares by region
  • 1.1.2 Market shares by product category
  • 1.1.3 Market shares by species
• 1.2 The animal health and nutrition products industry
  • 1.2.1 Leading companies in the animal health and nutrition sector
    • 1.2.1.1 Market leaders in 2005
    • 1.2.1.2 Market leaders in 2006
  • 1.2.2 Industry profit levels
• 1.3 Currencies and exchange rates used in this report

CHAPTER 2 ADISSEO

• 2.1 Company background
• 2.2 Animal nutrition sales
  • 2.2.1 2004 performance
  • 2.2.2 2005 performance
  • 2.2.3 Interim 2006 performance
• 2.3 Geography of the business
  • 2.3.1 Europe, Middle East, Africa and CIS
  • 2.3.2 Asia/Pacific
  • 2.3.3 Latin America
  • 2.3.4 North America
• 2.4 Product portfolio
  • 2.4.1 Methionine
  • 2.4.2 Vitamins
  • 2.4.3 Enzymes
• 2.5 R&D
• 2.6 Strategy
• 2.7 Prospects

CHAPTER 3 ALPHARMA

• 3.1 Company background
• 3.2 Animal health sales and operating profit
  • 3.2.1 2004 performance
  • 3.2.2 2005 performance
  • 3.2.3 Interim 2006 performance
• 3.3 Geography of the business
  • 3.3.1 US
  • 3.3.2 International markets
• 3.4 Product portfolio
  • 3.4.1 Antibiotics
  • 3.4.2 Anticoccidials
  • 3.4.3 Antibacterials
  • 3.4.4 Other products
• 3.5 R&D
• 3.6 Strategy
• 3.7 Prospects

CHAPTER 4 BASF

• 4.1 Company background
• 4.2 Animal nutrition sales
  • 4.2.1 2004 performance
  • 4.2.2 2005 performance
  • 4.2.3 Interim 2006 performance
• 4.3 Geography of the business
  • 4.3.1 Europe
  • 4.3.2 Americas
  • 4.3.3 Asia/Pacific
• 4.4 Product portfolio
  • 4.4.1 Vitamins
  • 4.4.2 Amino acids
  • 4.4.3 Carotenoids
  • 4.4.4 Enzymes
  • 4.4.5 Other products
• 4.5 R&D
• 4.6 Strategy
• 4.7 Prospects

CHAPTER 5 BAYER

• 5.1 Company background
• 5.2 Animal health sales and operating income
  • 5.2.1 2004 performance
  • 5.2.2 2005 performance
  • 5.2.3 Interim 2006 performance
• 5.3 Geography of the business
  • 5.3.1 North America
  • 5.3.2 Europe
  • 5.3.3 Asia/Pacific
  • 5.3.4 Latin America, Africa & Middle East
• 5.4 Product portfolio
  • 5.4.1 Antiparasitics
  • 5.4.2 Antimicrobials
  • 5.4.3 Other products
• 5.5 R&D
• 5.6 Strategy
• 5.7 Prospects

CHAPTER 6 BOEHRINGER INGELHEIM

• 6.1 Company background
• 6.2 Animal health sales
  • 6.2.1 2004 performance
  • 6.2.2 2005 performance
  • 6.2.3 Interim 2006 performance
• 6.3 Geography of the business
  • 6.3.1 Europe
  • 6.3.2 North America
  • 6.3.3 Other markets
• 6.4 Product portfolio
  • 6.4.1 Pharmaceuticals
  • 6.4.2 Biologicals
  • 6.4.3 Other products
• 6.5 R&D
• 6.6 Strategy
• 6.7 Prospects

CHAPTER 7 CEVA

• 7.1 Company background
• 7.2 Animal health sales and earnings
  • 7.2.1 2004 performance
  • 7.2.2 2005 performance
  • 7.2.3 Interim 2006 performance
• 7.3 Geography of the business
  • 7.3.1 Europe
  • 7.3.2 International markets
• 7.4 Product portfolio
  • 7.4.1 Companion animal and behavioral products
  • 7.4.2 Reproductive controls
  • 7.4.3 Anti-infectives
  • 7.4.4 Vaccines
  • 7.4.5 Others
• 7.5 R&D
• 7.6 Strategy
• 7.7 Prospects

CHAPTER 8 DAINIPPON SUMITOMO PHARMA

• 8.1 Company background
• 8.2 Animal health sales and operating profit
  • 8.2.1 Fiscal 2005 performance
  • 8.2.2 Fiscal 2006 performance
• 8.3 Geography of the business
• 8.4 Product portfolio
  • 8.4.1 Companion animal products
  • 8.4.2 Food animal products
• 8.5 R&D
• 8.6 Strategy
• 8.7 Prospects

CHAPTER 9 DEGUSSA

• 9.1 Company background
• 9.2 Feed additive sales
  • 9.2.1 2004 performance
  • 9.2.2 2005 performance
  • 9.2.3 Interim 2006 performance
• 9.3 Geography of the business
• 9.4 Product portfolio
  • 9.4.1 Methionine
  • 9.4.2 Other amino acids
• 9.5 R&D
• 9.6 Strategy
• 9.7 Prospects

CHAPTER 10 DSM

• 10.1 Company background
• 10.2 Animal nutrition sales
  • 10.2.1 2004 performance
  • 10.2.2 2005 performance
  • 10.2.3 Interim 2006 performance
• 10.3 Geography of the business
• 10.4 Product portfolio
  • 10.4.1 Vitamins
  • 10.4.2 Carotenoids
  • 10.4.3 Feed enzymes
  • 10.4.4 Other products
• 10.5 R&D
• 10.6 Strategy
• 10.7 Prospects

CHAPTER 11 ELANCO

• 11.1 Company background
• 11.2 Animal health sales and operating income
  • 11.2.1 2004 performance
  • 11.2.2 2005 performance
  • 11.2.3 Interim 2006 performance
• 11.3 Geography of the business
  • 11.3.1 US
  • 11.3.2 International markets
• 11.4 Product portfolio
  • 11.4.1 Tylosin
  • 11.4.2 Tilmicosin
  • 11.4.3 Monensin
  • 11.4.4 Avilamycin
  • 11.4.5 Ractopamine
  • 11.4.6 Other products
• 11.5 R&D
• 11.6 Strategy
• 11.7 Prospects

CHAPTER 12 FORT DODGE

• 12.1 Company background
• 12.2 Animal health sales and operating profit
  • 12.2.1 2004 performance
  • 12.2.2 2005 performance
  • 12.2.3 Interim 2006 performance
• 12.3 Geography of the business
  • 12.3.1 US
  • 12.3.2 International markets
• 12.4 Product portfolio
  • 12.4.1 Biologicals
  • 12.4.2 Antiparasitics
  • 12.4.3 Other pharmaceuticals
• 12.5 R&D
• 12.6 Strategy
• 12.7 Prospects

CHAPTER 13 IDEXX

• 13.1 Company background
• 13.2 Sales and income
  • 13.2.1 2004 performance
  • 13.2.2 2005 performance
  • 13.2.3 Interim 2006 performance
• 13.3 Geography of the business
  • 13.3.1 North America
  • 13.3.2 International markets
• 13.4 Product portfolio
  • 13.4.1 Companion animal group
    • 13.4.1.1 Immunoassays
    • 13.4.1.2 Veterinary instrument systems
    • 13.4.1.3 Reference laboratory and consulting services
    • 13.4.1.4 Information management and radiography
    • 13.4.1.5 Veterinary pharmaceuticals
  • 13.4.2 Water products and services
  • 13.4.3 Food diagnostics group
• 13.5 R&D
• 13.6 Strategy
• 13.7 Prospects

CHAPTER 14 INTERVET

• 14.1 Company background
• 14.2 Animal health sales and operating profit
  • 14.2.1 2004 performance
  • 14.2.2 2005 performance
  • 14.2.3 Interim 2006 performance
• 14.3 Geography of the business
  • 14.3.1 Europe
  • 14.3.2 Americas
  • 14.3.3 Other markets
• 14.4 Product portfolio
  • 14.4.1 Biologicals
  • 14.4.2 Antiparasitics
  • 14.4.3 Anti-infectives
  • 14.4.4 Other products
• 14.5 R&D
• 14.6 Strategy
• 14.7 Prospects

CHAPTER 15 MERIAL

• 15.1 Company background
• 15.2 Animal health sales
  • 15.2.1 2004 performance
  • 15.2.2 2005 performance
  • 15.2.3 Interim 2006 performance
• 15.3 Geography of the business
• 15.3.1 US
  • 15.3.2 Europe
  • 15.3.3 International
• 15.4 Product portfolio
  • 15.4.1 Avermectins
  • 15.4.2 Fipronil
  • 15.4.3 Biologicals
  • 15.4.4 Other products
• 15.5 R&D
• 15.6 Strategy
• 15.7 Prospects

CHAPTER 16 NOVARTIS

• 16.1 Company background
• 16.2 Animal health sales and operating profit
  • 16.2.1 2004 performance
  • 16.2.2 2005 performance
  • 16.2.3 Interim 2006 performance
• 16.3 Geography of the business
  • 16.3.1 North America
  • 16.3.2 Europe
  • 16.3.3 Other markets
• 16.4 Product portfolio
  • 16.4.1 Antiparasitics
  • 16.4.2 Anti-infectives
  • 16.4.3 Other pharmaceuticals
  • 16.4.4 Vaccines
• 16.5 R&D
• 16.6 Strategy
• 16.7 Prospects

CHAPTER 17 PFIZER

• 17.1 Company background
• 17.2 Animal health sales and operating profit
  • 17.2.1 2004 performance
  • 17.2.2 2005 performance
  • 17.2.3 Interim 2006 performance
• 17.3 Geography of the business
  • 17.3.1 US
  • 17.3.2 International markets
• 17.4 Product portfolio
  • 17.4.1 Anti-infectives
  • 17.4.2 Antiparasitics
  • 17.4.3 Vaccines
  • 17.4.4 Other pharmaceuticals
• 17.5 R&D
• 17.6 Strategy
• 17.7 Prospects

CHAPTER 18 PHIBRO

• 18.1 Company background
• 18.2 Animal health & nutrition sales and operating profit
  • 18.2.1 Fiscal 2004 performance
  • 18.2.2 Fiscal 2005 performance
  • 18.2.3 Interim fiscal 2006 performance
• 18.3 Geography of the business
• 18.4 Product portfolio
  • 18.4.1 Phibro Animal Health
  • 18.4.2 Koffolk
  • 18.4.3 Prince Agri Products
• 18.5 R&D
• 18.6 Strategy
• 18.7 Prospects

CHAPTER 19 SCHERING-PLOUGH

• 19.1 Company background
• 19.2 Animal health sales and earnings
  • 19.2.1 2004 performance
  • 19.2.2 2005 performance
  • 19.2.3 Interim 2006 performance
• 19.3 Geography of the business
  • 19.3.1 US
  • 19.3.2 International markets
• 19.4 Product portfolio
  • 19.4.1 Antiparasitics
  • 19.4.2 Anti-infectives
  • 19.4.3 Vaccines
  • 19.4.4 Other products
• 19.5 R&D
• 19.6 Strategy
• 19.7 Prospects

CHAPTER 20 VETOQUINOL

• 20.1 Company background
• 20.2 Animal health sales
  • 20.2.1 2004 performance
  • 20.2.2 2005 performance
  • 20.2.3 Interim 2006 performance
• 20.3 Geography of the business
  • 20.3.1 Europe
  • 20.3.2 North America
  • 20.3.3 Other markets
• 20.4 Product portfolio
  • 20.4.1 Anti-infectives
  • 20.4.2 Other pharmaceuticals
  • 20.4.3 Other products
• 20.5 R&D
• 20.6 Strategy
• 20.7 Prospects

CHAPTER 21 VIRBAC

• 21.1 Company background
• 21.2 Animal health sales and operating profit
  • 21.2.1 2004 performance
  • 21.2.2 2005 performance
  • 21.2.3 Interim 2006 performance
• 21.3 Geography of the business
  • 21.3.1 Europe
  • 21.3.2 North America
  • 21.3.3 Other markets
• 21.4 Product portfolio
  • 21.4.1 Antiparasitics
  • 21.4.2 Anti-infectives
  • 21.4.3 Biologicals
  • 21.4.4 Other products
• 21.5 R&D
• 21.6 Strategy
• 21.7 Prospects